Inovio Pharmaceuticals, Inc. (INO)
-NYSE MKT | Prev Close: | 2.13 |
|---|
| Open: | N/A |
|---|
| Bid: | 2.10 x 200 |
|---|
| Ask: | 2.21 x 500 |
|---|
| 1y Target Est: | 2.80 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.44 - 3.03 |
|---|
| Volume: | 200 |
|---|
| Avg Vol (3m): | 10,433,400 |
|---|
| Market Cap: | 404.49M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor ForumPR Newswire(Tue, Oct 1)
- 3 Biotech Stocks To Trade But For Different Reasonsat Seeking Alpha(Tue, Sep 24)
- Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody TherapiesPR Newswire(Tue, Sep 24)
- Trade-Ideas: Inovio Pharmaceuticals (INO) Is Today's "Dead Cat Bounce" Stockat TheStreet(Mon, Sep 23)
- [$$] Less Down on Dendreonat Barrons.com(Thu, Sep 19)
- Is Roche a Small Biotech's Best Friend?at Motley Fool(Wed, Sep 18)
- Inovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los AngelesPR Newswire(Wed, Sep 18)
- Organovo May Be Big Pharma's Salvationat Seeking Alpha(Tue, Sep 17)
- Inovio Pharmaceuticals: Features Of A Quality Biotechat Seeking Alpha(Mon, Sep 16)
- This Week in Biotechat Motley Fool(Sat, Sep 14)
- Inovio: All Signs Point Upat Seeking Alpha(Fri, Sep 13)
- INOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Thu, Sep 12)
- What Does Roche's Inovio Deal Mean for Investors?at Motley Fool(Wed, Sep 11)
- Roche and Inovio Tie UpZacks(Wed, Sep 11)
- Inovio's Partnership & It's Many Benefitsat Seeking Alpha(Wed, Sep 11)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 95.62 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.17 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.02 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases.
View More
0.41%